BioAge Labs, Inc.
Market Cap
$760.84M
P/E Ratio
1.56
EPS
$13.61
Dividend Yield
0.00%
52-Week Range
$2.88 — $24.00
Volume
436.74K
Avg Volume
702.34K
Beta
1.24
P/E (TTM)
1.56
Forward P/E
—
PEG Ratio
-0.14
P/S (TTM)
113.44
P/B (TTM)
2.42
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
-0.25%
ROA (TTM)
-0.25%
ROIC
—
Gross Margin
1.00%
Operating Margin
-15.16%
Net Margin
—
Debt/Equity
0.03
Current Ratio
11.87
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
-0.13%
EPS Growth (5Y)
-0.13%
Sales Growth (3Y)
+0.00%
Sales Growth (5Y)
+0.00%
EPS Est (This Year)
$-2.85
EPS Est (Next Year)
$-2.70
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$7.97
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
35.86M
Float
22.74M
Free Float %
63.41%
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
NASDAQ
IPO Date
2024-09-26
Employees
62
CEO
Kristen Fortney
Index Membership
—
Website
https://bioagelabs.com
BioAge Labs, Inc. (BIOA) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $760.84M, a P/E ratio of 1.56, BIOA is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare BIOA against other stocks using dozens of fundamental and technical filters.
BioAge Labs, Inc. (BIOA) has a trailing twelve-month (TTM) P/E ratio of 1.56. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, BioAge Labs, Inc. (BIOA) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
BioAge Labs, Inc. (BIOA) has a market capitalization of $760.84 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.